Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients
β Scribed by Eng-Hen Ng; Chen-Yang Ji; Puay-Hoon Tan; Valerie Lin; Khee-Chee Soo; Kok-Onn Lee
- Publisher
- Springer
- Year
- 1998
- Tongue
- English
- Weight
- 671 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1068-9265
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Insulin-like growth factors (IGFs) are potent mitogens involved in the regulation of cell proliferation and apoptosis. The action of IGFs is mediated through a specific cell membrane receptor (IGF-IR), and the interactions between IGFs and this receptor are regulated by IGF-binding proteins (IGFBPs)
The mitogenic effects of insulin-like growth factors (IGFs) are regulated by a family of insulin-like growth factor binding proteins (IGFBPs). One member of this family, IGFBP-3, mediates the growth-inhibitory and apoptosis-inducing effects of a number of growth factors and hormones such as transfor
## Abstract Recent epidemiological studies have shown that high serum levels of insulinβlike growth factorβI (IGFβI) are associated with an increased risk of lung, colon, breast and prostate cancer. Since very few studies have addressed the role of serum levels of IGFβI in the development of pancre
Insulin-like growth factors (IGF)-I and -II are bound to carrier or binding proteins in serum. There are at least two classes of binding protein: a high molecular weight complex and a low molecular weight species that is relatively unsaturated. Total binding capacity in serum generally is determined